Company / EPS (Diluted)
Apellis Pharmaceuticals, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$4.45
FY2025
5-year range
-$8.84 / -$4.45
FY2021-FY2025
Trend
+27.6%
vs FY2024
Sector context
#168 of 204
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s eps (diluted) of $-4.45 is lower than 82% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 6 years, ranging from $-8.84 in FY2023 to $-2.34 in FY2020.
Based on SEC 10-K filings.
-4.45 in FY2025.
Improved from $-8.84 to $-4.45 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 204This company -$4.45 Sector average -$0.89
▼
-402.1% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 27.6% year-over-year.
- Ranks #168 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.45 | +27.6% |
| FY2024 | -$6.15 | +30.4% |
| FY2023 | -$8.84 | -92.6% |
| FY2022 | -$4.59 | +6.3% |
| FY2021 | -$4.90 | -109.4% |
| FY2020 | -$2.34 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026